Related Experiment Videos
The evolution of therapy for patients with stage IIIA (N2) lung cancer
1Duke Thoracic Oncology Program, Duke University Comprehensive Cancer Center, Durham, NC, USA.
Chest
|October 23, 1997
Abstract:
This is a demonstrable case report and discussion of recent trends in neoadjuvant therapy for patients with locally advanced stage IIIA (N2) non-small cell lung cancer.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Predicting the sites of metastases from lung cancer using molecular biologic markers.
The Annals of thoracic surgery·2001
Tumor marker expression is predictive of survival in patients with esophageal cancer.
The Annals of thoracic surgery·2001
Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands)·2001
The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Staging techniques for lung cancer.
Chest surgery clinics of North America·2000
Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared decision-making.
Expert review of anticancer therapy·2026
Atypical cytokine release syndrome induced by carboplatin: The first described case report.
International journal of immunopathology and pharmacology·2026
Effects of X-ray and carbon-ion beam irradiation on pathological cardiac remodeling in mice.
Journal of radiation research·2026
Applying Retrorectal Oncologic Tumor Dissection Planes to a Pelvic Tailgut Cyst.
The American surgeon·2026